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Small cell carcinoma presenting as a biatrial
mass with obstructive physiology: a case report
Sara Ratican1*†, Soomin Shin2† and John Moretto2

Abstract
Background: Small cell carcinoma is a highly aggressive and often fatal cancer that most commonly arises in the
lung, although it can occasionally arise from other sites, such as the gastrointestinal tract, prostate or cervix. Cardiac
involvement, however, is extremely uncommon and therefore has been poorly documented in the literature.
Case presentation: We describe a rare case of a 31-year-old male with small cell carcinoma presenting as a massive,
15-cm cardiac tumor invading the bilateral atria, interatrial septum, and pericardium without an apparent primary
malignancy on PET CT and cardiac MRI. With extensive tissue necrosis, traditional methods of obtaining a right atrial
endomyocardial biopsy via internal jugular venous access failed and a diagnosis was made via endoscopic ultrasound
guided transesophageal fine needle aspiration of the left atrial mass. Due to the extensive tumor invasion, the patient
was not a suitable candidate for surgical resection, debulking, or heart transplant. The patient was treated with etoposide, carboplatin, atezolizumab, and radiation therapy with initial monitoring in the intensive care unit due to concern
that tumor lysis may cause rapid cardiac decompensation. Unfortunately, 4 months after chemoradiation therapy, the
malignancy progressed and the patient passed away 6 months after the initial diagnosis.
Conclusion: We describe a rare occurrence of small cell carcinoma presenting as a massive cardiac tumor without
apparent primary malignancy. This case demonstrates useful alternative diagnostic strategies and treatment considerations for patients presenting with a rare cardiac mass.
Keywords: Cardiac tumor, Small cell carcinoma, EUS-FNA
Background
Small cell carcinoma is a highly aggressive and often fatal
cancer that most commonly arises in the lung, although
it can occasionally arise from other sites, such as the gastrointestinal tract, prostate, or cervix. It most frequently
metastasizes to the mediastinal lymph nodes, liver, bone,
adrenals and brain [1]. Cardiac involvement is extremely
uncommon and therefore has been poorly documented
in the literature [1–3]. We describe a rare occurrence
of small cell carcinoma presenting as a massive cardiac
tumor invading bilateral atria, interatrial septum and
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pericardium with obstructive physiology and without
apparent primary malignancy. This case demonstrates
useful alternative diagnostic strategies and treatment
considerations for patients presenting with a rare cardiac
mass.

Case presentation
A 31-year-old male with a history significant for exposure
to secondhand smoke but no other medical diagnoses
presented with shortness of breath for 6 weeks. On exam,
he was in atrial flutter with rapid ventricular response
and had signs of heart failure with lower extremity
edema. CT pulmonary angiogram showed evidence of
bilateral pulmonary embolisms and a 15-cm mass occupying both atria, obliterating the interatrial septum, and
invading into the pericardium. The features of cardiac
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mass were further characterized by echocardiogram
(Figs. 1 and 2) and cardiac MRI (Fig. 3). PET scan showed
hypermetabolic activity of the cardiac mass concerning
for malignancy, but did not demonstrate any other areas
of hypermetabolic activity (Fig. 4) to suggest an extracardiac primary malignancy.
To further characterize the tumor, we proceeded with
numerous attempts for endomyocardial biopsy in the
right atrium via internal jugular vein access. Unfortunately, all samples were non-diagnostic and yielded only
necrotic cellular debris. Therefore, the decision was made

Fig. 3 Cardiac MRI with contrast showing neoplasm with biatrial and
pericardial invasion, approximately 15 cm in diameter

Fig. 1 Echocardiogram with apical four-chamber view showing large
atrial mass occupying both left atrium and right atrium, obliterating
the interatrial septum

Fig. 4 18F-FDG PET/CT scan showing hypermetabolic cardiac mass
without alternative primary malignancy

Fig. 2 Echocardiogram with subcostal four-chamber view showing
large atrial mass occupying both left atrium and right atrium,
obliterating the interatrial septum

to use an alternative approach, obtaining a left atrial mass
biopsy via endoscopic ultrasound (EUS) guided fine needle aspiration (FNA), taking advantage of the fact that the
left atrium sits anterior to the esophagus. The patient tolerated the EUS-guided transesophageal endomyocardial
biopsy without complications (Fig. 5).
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Fig. 5 Upper endoscopic ultrasound-guided fine needle aspiration
of the cardiac tumor

The pathology report revealed flow cytometry results,
immunohistochemistry findings and cell morphology
that were consistent with a diagnosis of small cell neuroendocrine carcinoma. Direct smears and cell block
slides showed numerous, loosely cohesive cells with high
nuclear-to-cytoplasmic ratio, some nuclear molding
and hyper-chromatic nuclei without prominent nucleoli (Fig. 6C). The tumor was positive for synaptophysin,
CAM 5.2 and CD56 and negative for CD19 and TTF-1
(Fig. 6A-B). There was no immunohistochemical staining present that would suggest a primary GI tumor origin. While the tumor lacked staining for TTF-1, which is
usually present in pulmonary small cell carcinoma, this
marker has been found to be negative in up to 17% of
cases [4]. Based on the presentation, it was hypothesized
that the patient’s cardiac mass was likely a metastasis
from a primary pulmonary lesion that was too small to be
detected by MRI or PET. However, further evaluation via
sputum cytology or bronchoscopy was not performed.
The patient was successfully converted from atrial
flutter to normal sinus rhythm on amiodarone. His
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bilateral pulmonary emboli were effectively treated with
an unfractionated heparin infusion, which was later
transitioned to dabigatran. Due to the extensive tumor
invasion, the patient was not a candidate for surgical
resection, debulking, or heart transplant. In the hospital,
he was started on etoposide 100 mg/m2 for 3 days and
carboplatin therapy AUC 5 IV over day 1. The patient’s
first round of chemotherapy was monitored in the intensive care unit due to the possibility of tumor lysis leading
to rapid cardiac decompensation. The patient tolerated
the first round of chemotherapy without complications.
Following discharge, atezolizumab (1200 mg IV, 21 day
cycle) and radiation therapy (5940 cGy, 33 sessions) were
added to his treatment plan. Unfortunately, 4 months
after chemoradiation therapy, the patient was found to
have extensive epidural involvement with cauda equina
syndrome. He was transitioned to hospice and passed
away 6 months after the diagnosis.

Discussion and conclusions
Most cardiac tumors are results of metastatic malignancy. In a large review of 12,485 autopsy cases, only 154
secondary tumors (1.25%) and 7 primary cardiac tumors
(0.056%) were identified [5]. More than one third of cardiac metastases originate from lung cancer, with approximately 20% arising from non solid primary malignancies
such as lymphoma, leukemia and Kaposi sarcoma, 7%
from breast carcinoma and 6% from carcinoma of the
esophagus [1, 6]. Common routes of metastasis include
direct invasion, hematogenous seeding, lymphatic
spread, and intracavitary extension from the inferior vena
cava [7]. Primary cardiac tumors are rare, and only about
15% of the primary cardiac tumors are malignant [8, 9].
Of the malignant tumors, the vast majority are sarcoma,
followed by cardiac lymphoma and pericardial mesothelioma [10].

Fig. 6 Cardiac Tumor fine needle aspiration (FNA) Pathology. A TM Cardiac FNA cell block with synaptophysin IHC stain showing strong positivity,
400x. B TM Cardiac FNA cell block with CAM 5.2 IHC dot-like staining, 400x. C TM Cardiac FNA Diff-Quik stained smear showing discohesive tumor
cells, 400X
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Cardiac tumors have a wide range of clinical manifestations. Its signs and symptoms are generally determined
by its location and size, rather than its histology type [6].
Invasive tumors can cause valvular dysfunction, conduction abnormalities, and impaired myocardial contractility
[10]. Tumors can embolize systematically to cause pulmonary embolism and end-organ failure. This case is an
extreme example of cardiac tumor invasion presenting
with a multitude of cardiac symptoms, including newonset atrial flutter, pulmonary embolism, and obstructive
right heart hemodynamics.
The initial diagnostic part of the case was uniquely
challenging. Our initial endomyocardial biopsy via
internal jugular vein was not diagnostic due to the profound tissue necrosis in the left atrium. An alternative
route of biopsy needed to be explored. The standard
approach to endomyocardial biopsy uses a transvenous
approach that was first developed in 1962 when the
Konno-Sakakibara bioptome was invented [11]. Since
then, this technique has been refined and improved
to become the standard practice for diagnosis of infiltrative cardiomyopathies and surveillance of heart
transplant rejection. A handful of case reports have
demonstrated the feasibility of both right atrial and left
atrial masses biopsy using the EUS-FNA approach for
diagnosis of cardiac sarcoma, cardiac lymphoma, and
cardiac myxoma [12, 13]. While both procedures carry
potential risks, in theory cardiac EUS-FNA has advantages over transvascular biopsies, such as real-time
targeting of the lesion, avoiding damage to the valves
or the coronary arteries during puncture, faster performance, and elimination of the need for fluoroscopy [13].
This case highlights the importance of considering various approaches to endomyocardial biopsy and confers
both the feasibility and safety of utilizing endoscopic
ultrasound guidance for left atrial biopsy.
Management of atrial masses is generally surgical if
tumors are benign or resectable without evidence of
metastasis [14]. Based on the histopathologic finding of
this case, the patient’s cardiac mass is likely a metastatic
disease from a primary pulmonary lesion, presumably
too small to be detected by MRI or PET. However, further
evaluation via sputum cytology or bronchoscopy was not
performed at the time. Small cell carcinoma presenting
as a cardiac mass has only been described in a handful
of case studies [1–3, 15] with the majority documenting
a primary pulmonary lesion. An extrapulmonary small
cell carcinoma of cardiac origin would be incredibly rare,
with only one potential case ever reported in the literature [2].
The backbone of managing metastatic small cell
carcinoma is a combination of systemic chemotherapy with cisplatin or carboplatin and etoposide [16].
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Recently, the addition of atezolizumab, a monoclonal antibody against PD-L1, has been approved by the
U.S. Food and Drug Administration to be used in combination with carboplatin and etoposide as first-line
therapy [17]. In extensive metastatic disease, radiation
therapy can be used to treat symptomatic sites such as
the brain, bone, or spinal metastasis. The role of chest
radiation for metastatic small cell carcinoma presenting as cardiac mass is not clear but has been reported
in one case report showing tumor regression without
adverse events [3]. While surgical resection, chemotherapy or radiation therapy may be used for palliation
in some cases, the overall prognosis for malignant cardiac tumors, both primary and secondary, is poor [15].
The prognosis of pulmonary small cell carcinoma is
also poor with a 5-year survival rate of 6.3% [18].
With the extensive invasion of cardiac tissue by the
tumor, treatment planning required us to weigh the benefits of chemotherapy for disease palliation against its
potential adverse effects on the heart’s structural integrity. Although small cell carcinoma is an aggressive disease, it is initially quite sensitive to chemotherapy and
radiotherapy [16]. The main cardiac risks of treatment
included myocardial free rupture or development of a
large atrial septal defect with lysis of the tumor, leading to
rapid cardiac decompensation. As such, the patient was
monitored in the intensive care unit while receiving his
first round of chemotherapy.
We describe a rare occurrence of small cell carcinoma
presenting as a massive cardiac tumor without apparent
primary malignancy. Due to the tumor’s extensive invasion into the bilateral atria, interatrial septum and pericardium, alternative biopsy strategies and treatment
considerations needed to be pursued. These options
may inform the care of future patients presenting with
an extensive malignant cardiac mass.
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